| abstract |
The present disclosure provides [1,2,4]triazolo[4,3- b ][1,2,4]triazine, [1,2,4] triazolo[4,3- b ]pyridazine, and [1,2,3]triazolo[4,5- b ]pyrazine derivatives, and pharmaceutically acceptable salts, solvates or prodrugs thereof, as tyrosine kinase c-MET inhibitors, which are useful as novel anticancer and/or anti-inflammatory agents. |